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General	Methods	
All commercial solvents and reagents were used as obtained without further purification, except for CH2Cl2 
which was distilled before use. Water was purified by a Milli-Q system and degassed by letting through 
nitrogen gas. All reactions were carried out under a nitrogen atmosphere. Semi-automatic flash 
chromatography was performed using Merck silica gel 60 (0.040-0.063 mm), on a Biotage HPFC SP4 Flash 
Purification System. 1H and 13C NMR spectra were recorded at 300 K on a Bruker Avance III 400 operating 
at 400 MHz and 101 MHz, respectively, with chemical shifts calibrated relative to solvent residual peaks (1H 
NMR (DMSO-d6): δ 2.50 ppm; 1H NMR (CDCl3): δ 7.26 ppm; 13C NMR (DMSO-d6): δ 39.52 ppm; 13C 
NMR (CDCl3): δ 77.16 ppm). Assignments are based on chemical shifts and/or COSY, HSQC and NOESY 
spectra. Mass spectra were recorded on a Bruker MicroTOF-Q II (ESI) spectrometer. Reactions were 
monitored by thin-layer chromatography (TLC) carried out on 0.25 mm E. Merck silica gel plates (60F-254) 
using UV-light and HPLC using a Dionex 120A C18 column (5µ, 4.6x150 mm) with gradient elution of 
MeCN and water, both solvents containing 0.05% trifluoroacetic acid (TFA), at a flow rate of 1 mL min-1 
and UV detection at 230, 254 and 320 nm. HPLC purification was performed by using a Phenomenex Luna 
C18 5μ column (250x21.20 mm) with gradient elution of MeCN and water, both solvents containing 0.05% 
TFA, at a flow rate of 20 mL min-1.  
Synthesis	of	phenanthroline	ligands	
Ligands L1(DPPhen)1 and G2 were prepared as described previously.  
 
N4,N7-Dimethyl-1,10-phenanthroline-4,7-diamine (Ligand L2) 
 
A sealed vial containing 4,7-dichloro-1,10-phenanthroline (300 mg, 1.2 mmol) and methylamine (5.0 mL, 
33% in EtOH, 40 mmol) was heated in a microwave reactor (Emrys Creator) at 150 °C for 40 min to give an 
orange mixture with a precipitate. The precipitate was isolated by filtration, washed with water, ethanol and 
diethyl ether, and dried under vacuum to give the title compound as a pale yellow solid (255 mg, 89% yield). 
m.p. > 250 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.73 (s, 2H), 8.53 (d, J = 6.2 Hz, 2H), 8.36 (s, 2H), 6.84 (d, 
J = 6.3 Hz, 2H), 3.04 ppm (d, J = 4.4 Hz, 6H); 13C NMR (101 MHz, DMSO-d6) δ 153.6, 145.8, 137.3, 118.2, 
117.0, 101.1, 29.7 ppm. HRMS-ESI: m/z calcd for C14H15N4+: 239.1291 [M+H+], found: 239.1298. 
 
N4,N7-Bis(2-hydroxyethyl)-1,10-phenanthroline-4,7-diamine (Ligand L3, BHPhen) 
  
A sealed vial containing 4,7-dichloro-1,10-phenanthroline (747 mg, 3.0 mmol), 2-aminoethanol (1.81 mL, 
30.0 mmol) and anhydrous EtOH (15.0 mL) was heated in a microwave reactor (Biotage Initiator+ EU) at 
140 °C for 3 hours to give a red mixture with a precipitate. The precipitate was isolated by filtration, washed 
sequentially with water, ethanol and diethyl ether, and dried under vacuum to give the title compound as a 
pale yellow solid (795 mg, 89% yield). m.p. > 250 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.48 (d, J = 5.3 Hz, 
2H), 8.06 (s, 2H), 7.19–7.03 (m, 2H), 6.67 (d, J = 5.4 Hz, 2H), 4.91 (s, 2H), 3.70 (t, J = 5.7 Hz, 4H), 3.42–
3.35 ppm (m, 4H); 13C NMR (101 MHz, DMSO-d6) δ 150.2, 149.4, 146.3, 117.4, 117.2, 100.7, 58.9, 45.3 
ppm. HRMS-ESI: m/z calcd for C16H19N4O2+: 299.1503 [M+H+], found: 299.1514. 
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Table	S1:	Ligand	screening	for	the	coupling	of	adenine	and	iodobenzene	
 
entry ligand 
temp 
(°C) 
conversion 
(%)b 
yield 
(%)c 
1 A 100 <1 ND 
2 B 100 6 ND 
3 C 100 2 ND 
4 D 100 13 ND 
5 E 100 <1 ND 
6 L1 100 22 19 
7 L2 100 31 20 
8 F 120 32 30 
9 G 120 <1 ND 
10 L1 120 65 46 
11 L2 120 ND 56 
 
Reaction conditions: 1 (0.60 mmol), iodobenzene (0.50 mmol), ligand (10 mol %), CuBr (5 mol %), KOH (1.0 mmol), 
EtOH/H2O (1.0 mL, 4:1), heated in a sealed vial to 100 °C or 120 °C for 18 h. b Determined from integration of the area 
under the signal of 2 (HPLC; UV absorbtion at 254 nm) as the percentage of the total area of the signals corresponding 
to 1 and 2. c Yield of isolated product. ND: not determined. 
 	
S4 
 
Reaction	optimisation	
Entry 1: A reaction tube equipped with a magnetic stirring bar was charged with CuBr (3.6 mg, 0.025 
mmol), ligand (L1, 15.9 mg, 0.05 mmol), adenine (1, 81 mg, 0.60 mmol) and KOH (56.1 mg, 1.0 mmol). 
The tube was sealed with a rubber septum, evacuated and back-filled with nitrogen three times. EtOH/H2O 
(4:1 v/v, 1 mL) and iodobenzene (56 µL, 0.50 mmol) was added by syringe. The rubber septum was 
exchanged with a cap designed to withstand moderate pressure under a stream of nitrogen and the reaction 
tube was placed in a preheated oil bath at 120 °C. After 21 hours, the reaction mixture was cooled to RT, 
silica (1.5 g) was added and the mixture was concentrated to dryness on a rotary evaporator. The dry residue 
was purified by semi-automated flash column chromatography (Biotage SNAP 10 g, MeOH in CH2Cl2 (3% 
 5%)), to provide 49 mg (46%) of 9-phenyladenine (2).3 
Entries 2-19 were performed by the same procedure, but with the modifications indicated in Table 1. 
 
General	procedure	for	N9‐arylation	of	adenine	(Table	2)	
A reaction tube equipped with a magnetic stirring bar was charged with CuBr (3.6 mg, 0.025 mmol), ligand 
(L3, 14.9 mg, 0.05 mmol), sodium ascorbate (10 mg, 0.05 mmol), adenine (67.6 mg, 0.50 mmol), KOH 
(56.1 mg, 1.0 mmol) and aryl halide (if solid, 0.75 mmol). The reaction tube was sealed with a rubber 
septum, evacuated and back-filled with nitrogen three times. DMF/H2O (4:1 v/v, 1 mL) and aryl halide (if 
liquid, 0.75 mmol) was added by syringe. The rubber septum was exchanged with a cap designed to 
withstand moderate pressure under a stream of nitrogen and the reaction tube was placed in a preheated oil 
bath at 120 °C. After 21 hours (for aryl bromides 48 hours), the reaction mixture was cooled to RT, silica 
(1.5 g) was added and the mixture was concentrated to dryness on a rotary evaporator. The dry residue was 
purified by semi-automated flash column chromatography. In some cases an inorganic iodide salt eluted with 
the product on the column, which was removed by recrystallisation from H2O or MeOH. Known compounds 
exhibited 1H and 13C NMR in agreement with previously reported data cited below and ESI-MS was in 
agreement with the predicted molecular mass. 
 
3-(6-Aminopurin-9-yl)phenol (3a) 
  
Following the general procedure using 3-iodophenol (165 mg, 0.75 mmol) provided the title compound as a 
white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH2Cl2 (4%  7%)), 
followed by a recrystallisation from water. Yield: 101 mg (89%). m.p. >250 °C; 1H NMR (400 MHz, 
DMSO-d6) δ 9.89 (s, 1H), 8.54 (s, 1H), 8.22 (s, 1H), 7.45–7.29 (m, 4H), 7.29–7.24 (m, 1H), 6.88–6.78 ppm 
(m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 158.1, 156.3, 153.1, 149.1, 139.6, 136.1, 130.3, 119.4, 114.4, 
113.2, 110.0 ppm; HRMS-ESI: m/z calcd for C11H10N5O+: 228.0880 [M+H+], found: 228.0884. 
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9-(4-Aminophenyl)purin-6-amine (3b) 
  
Using 4-iodoaniline: Following the general procedure using 4-iodoaniline (164 mg, 0.75 mmol) and heating 
for 21 hours provided the title compound as a pale tan solid after semi-automated flash chromatography 
(Biotage SNAP 10 g, MeOH in CH2Cl2 (6%  10%)), followed by a recrystallisation from water. Yield: 100 
mg (88%).  
Using 4-bromoaniline: Following the general procedure using 4-bromoaniline (129 mg, 0.75 mmol) and 
heating for 48 hours provided the title compound as a pale tan solid after semi-automated flash 
chromatography (Biotage SNAP 25 g, 10% MeOH in CH2Cl2). Yield: 86 mg (76%). 
9-(4-Aminophenyl)purin-6-amine (3b): m.p. > 250 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.32 (s, 1H), 
8.14 (s, 1H), 7.38 (d, J = 8.6 Hz, 2H), 7.26 (s, 2H), 6.69 (d, J = 8.6 Hz, 2H), 5.36 ppm (s, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ 156.1, 152.7, 149.3, 148.4, 140.0, 124.6, 123.5, 119.0, 113.8 ppm; HRMS-ESI: m/z 
calcd for C11H11N6+: 227.1040 [M+H+], found: 227.1042. 
 
3-(6-Aminopurin-9-yl)benzoic acid (3c) 
 
N
NN
N
NH2
COOH  
Following the general procedure using 3-iodobenzoic acid (186 mg, 0.75 mmol) provided the title compound 
as a tan solid after semi-automated flash chromatography (Biotage SNAP 25 g, MeOH/AcOH 2:1 in CH2Cl2 
(6%  12%)), followed by a recrystallisation from MeOH. Yield: 84 mg (66%). m.p. >250 °C; 1H NMR 
(400 MHz, DMSO-d6) δ 13.32 (s, 1H), 8.68 (s, 1H), 8.51 (s, 1H), 8.32–8.20 (m, 1H), 8.19–8.11 (m, 1H), 
8.07–7.94 (m, 1H), 7.81–7.68 (m, 1H), 7.42 ppm (s, 2H); HRMS-ESI: m/z calcd for C12H10N5O2+: 256.0829 
[M+H+], found: 256.0831. 
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3-(6-Aminopurin-9-yl)benzonitrile (3d) 
  
Following the general procedure using 3-iodobenzonitrile (172 mg, 0.75 mmol) provided the title compound 
as an off-white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH2Cl2 
(4%  8%)), followed by a recrystallisation from H2O. Yield: 91 mg (77%). m.p. >250 °C; 1H NMR (400 
MHz, DMSO-d6) δ 8.71 (s, 1H), 8.48 (t, J = 1.7 Hz, 1H), 8.40–8.32 (m, 1H), 8.25 (s, 1H), 7.95–7.87 (m, 
1H), 7.81 (t, J = 8.0 Hz, 1H), 7.47 ppm (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.4, 153.4, 149.0, 
139.3, 135.9, 130.8, 130.8, 127.2, 125.8, 119.3, 118.1, 112.3 ppm; HRMS-ESI: m/z calcd for C12H9N6+: 
237.0883 [M+H+], found: 237.0881. 
 
9-(3-(Trifluoromethyl)phenyl)purin-6-amine (3e) 
  
Following the general procedure using 1-iodo-3-(trifluoromethyl)benzene (204 mg, 0.75 mmol) provided the 
title compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (4%  6%)). Yield: 116.5 mg (83%). m.p. 226-228°C; 1H NMR (400 MHz, DMSO-d6) δ 8.74 (s, 
1H), 8.40 (s, 1H), 8.33–8.26 (m, 1H), 8.25 (s, 1H), 7.88–7.76 (m, 2H), 7.46 ppm (s, 2H); 13C NMR (101 
MHz, DMSO-d6) δ 156.4, 153.4, 149.1, 139.5, 135.9, 130.8, 130.2 (q, J = 32.2 Hz), 126.4, 123.8 (q, J = 
272.5 Hz), 123.8 (q, J = 3.6 Hz), 119.3, 119.2 ppm (q, J = 3.9 Hz); HRMS-ESI: m/z calcd for C12H9F3N5+: 
280.0805 [M+H+], found: 280.0818. 
 
9-(3-Nitrophenyl)purin-6-amine (3f) 
  
Following the general procedure using 1-iodo-3-nitrobenzene (187 mg, 0.75 mmol) provided the title 
compound as a yellow solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  5%)), followed by a recrystallisation from water. Yield: 104 mg (81%). m.p. >250 °C; 1H 
NMR (400 MHz, DMSO-d6) δ 8.96 (t, J = 2.2 Hz, 1H), 8.80 (s, 1H), 8.48–8.40 (m, 1H), 8.31–8.24 (m, 2H), 
7.89 (t, J = 8.2 Hz, 1H), 7.49 ppm (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.4, 153.4, 149.1, 148.3, 
139.4, 136.2, 131.0, 128.4, 121.7, 119.3, 117.1 ppm; HRMS-ESI: m/z calcd for C11H9N6O2+: 257.0781 
[M+H+], found: 257.0794. 
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9-(2-Chlorophenyl)purin-6-amine (3g) 
  
Following the general procedure using 1-chloro-2-iodobenzene (179 mg, 0.75 mmol) provided the title 
compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  5%)). Yield: 2.2 mg (2%). m.p. 233-234 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H), 
8.11 (s, 1H), 7.79–7.73 (m, 1H), 7.69–7.64 (m, 1H), 7.64–7.53 (m, 2H), 7.39 ppm (s, 2H); 13C NMR (101 
MHz, DMSO-d6) δ 156.2, 153.2, 150.2, 140.6, 132.1, 131.0, 130.7, 130.2, 130.1, 128.3, 118.2 ppm; HRMS-
ESI: m/z calcd for C11H9ClN5+: 246.0541 [M+H+], found: 246.0553.4 
 
9-(o-Tolyl)purin-6-amine (3h) 
  
Following the general procedure using 2-iodotoluene (164 mg, 0.75 mmol) provided the title compound as a 
white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH2Cl2 (3%  5%). 
Yield: 7.5 mg (7%). 1H NMR (400 MHz, DMSO-d6) δ 8.26 (s, 1H), 8.11 (s, 1H), 7.49–7.45 (m, 2H), 7.40–
7.37 (m, 2H), 7.35 (s, 2H), 2.08 ppm (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.3, 153.0, 150.1, 140.8, 
134.9, 133.7, 131.0, 129.2, 127.8, 126.8, 118.4, 17.5 ppm; HRMS-ESI: m/z calcd for C12H12N5+: 226.1087 
[M+H+], found: 226.1088.5* 
 
9-(Pyridin-2-yl)purin-6-amine (3i) 
  
Following the general procedure using 2-bromopyridine (118 mg, 0.75 mmol) provided the title compound 
as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH2Cl2 (4%  
6%)). Yield: 87 mg (82%). m.p. 230-231 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.62–8.53 (m, 
2H), 8.29 (s, 1H), 8.15–8.07 (m, 1H), 7.54–7.40 ppm (m, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.4, 
153.3, 148.7, 148.7, 148.2, 139.5, 138.0, 122.7, 119.9, 115.1 ppm; HRMS-ESI: m/z calcd for C10H9N6+: 
213.0883 [M+H+], found: 213.0876. 
 
                                                     
* 1H NMR is not in agreement with that reported by Tao et al.5 No 13C NMR has been reported previously. 
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9-(6-Methylpyridin-3-yl)purin-6-amine (3j) 
  
Following the general procedure using 5-bromo-2-methylpyridine (129 mg, 0.75 mmol) provided the title 
compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  6%)). Yield: 92 mg (81%). m.p. 259-260 °C (dec.); 1H NMR (400 MHz, DMSO-d6) δ 8.95 
(d, J = 2.4 Hz, 1H), 8.61 (s, 1H), 8.27 – 8.16 (m, 2H), 7.48 (d, J = 8.4 Hz, 1H), 7.43 (s, 2H), 2.55 ppm (s, 
3H); 13C NMR (101 MHz, DMSO-d6) δ 157.0, 156.4, 153.3, 149.2, 143.1, 139.4, 130.9, 129.6, 123.4, 119.1, 
23.7 ppm; HRMS-ESI: m/z calcd for C11H11N6+: 227.1040 [M+H+], found: 227.1029. 
 
9-(Thiophen-3-yl)purin-6-amine (3k) 
  
Following the general procedure using 3-bromothiophene (122 mg, 0.75 mmol) provided the title compound 
as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in CH2Cl2 (4%  
8%)). Yield: 83 mg (76%). m.p. 218-219 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.65 (s, 1H), 8.24 (s, 1H), 
8.16 – 8.08 (m, 1H), 7.84 – 7.73 (m, 2H), 7.40 ppm (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 156.3, 153.3, 
148.7, 139.3, 133.3, 127.1, 121.8, 119.0, 114.5 ppm; HRMS-ESI: m/z calcd for C9H8N5S+: 218.0495 
[M+H+], found: 218.0487. 
 
4-(6-Aminopurin-9-yl)phenol (3l) 
  
Following the general procedure using 4-bromophenol (130 mg, 0.75 mmol) provided the title compound as 
a white solid after semi-automated flash chromatography (Biotage SNAP 25 g, 10% MeOH in CH2Cl2). 
Yield: 72 mg (63%). m.p. 303-305 °C (dec.); 1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 8.41 (s, 1H), 
8.17 (s, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.31 (s, 2H), 6.93 ppm (d, J = 8.8 Hz, 2H); 13C NMR (101 MHz, 
DMSO-d6) δ 156.8, 156.3, 153.0, 149.2, 139.9, 126.6, 124.9, 119.0, 115.8 ppm; HRMS-ESI: m/z calcd for 
C11H10N5O+: 228.0880 [M+H+], found: 228.0873. 
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1-(4-(6-Aminopurin-9-yl)phenyl)ethan-1-one (3m) 
  
Following the general procedure using 4’-bromoacetophenone (149 mg, 0.75 mmol) provided the title 
compound as a yellow solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  5%). Yield: 98 mg (77%). m.p. >250 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.74 (s, 1H), 
8.25 (s, 1H), 8.19–8.14 (m, 4H), 7.45 (s, 2H), 2.64 ppm (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 197.0, 
156.4, 153.4, 149.1, 139.3, 139.0, 135.1, 129.6, 122.0, 119.5, 26.8 ppm; HRMS-ESI: m/z calcd for 
C13H12N5O+: 254.1036 [M+H+], found: 254.1047. 
 
9-(4-Fluorophenyl)purin-6-amine (3n) 
  
Following the general procedure using 1-bromo-4-fluorobenzene (131 mg, 0.75 mmol) provided the title 
compound as a white solid after semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  5%)). Yield: 96 mg (84%). m.p. 255-256 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 
8.20 (s, 1H), 7.96–7.90 (m, 2H), 7.47–7.42 (m, 2H), 7.39 ppm (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 
160.9 (d, J = 244.4 Hz), 156.3, 153.2, 149.1, 139.7, 131.5 (d, J = 2.8 Hz), 125.2 (d, J = 8.6 Hz), 119.1, 116.3 
ppm (d, J = 22.9 Hz); HRMS-ESI: m/z calcd for C11H9FN5+: 230.0836 [M+H+], found: 230.0836.6 
 
2-(4-(6-Aminopurin-9-yl)phenyl)ethan-1-ol (3o) 
  
Following the general procedure using 4-bromophenethyl alcohol (151 mg, 0.75 mmol) provided the title 
compound as a white solid after semi-automated flash chromatography (Biotage SNAP 25 g, MeOH in 
CH2Cl2 (5%  8%)), followed by recrystallisation from H2O. Yield: 105 mg (82%). m.p. >250 °C; 1H NMR 
(400 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.20 (s, 1H), 7.80–7.73 (m, 2H), 7.44–7.40 (m, 2H), 7.37 (s, 2H), 4.70 
(t, J = 5.2 Hz, 1H), 3.65 (td, J = 6.9, 5.3 Hz, 2H), 2.80 ppm (t, J = 6.9 Hz, 2H); 13C NMR (101 MHz, DMSO-
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d6) δ 156.3, 153.1, 149.2, 139.6, 139.1, 133.1, 129.9, 122.8, 119.2, 62.0, 38.5 ppm; HRMS-ESI: m/z calcd for 
C13H14N5O+: 256.1193 [M+H+], found: 256.1204. 
 
9-(4-(2-Aminoethyl)phenyl)purin-6-amine (3p) 
  
Following the general procedure using 4-bromophenethyl amine (151 mg, 0.75 mmol) and EtOH/H2O (1 
mL, 4:1 v/v) as solvent provided the title compound as a pale yellow solid after semi-automated flash 
chromatography (Biotage SNAP 10 g, 24% NH3(aq)/MeOH 1:9 in CH2Cl2 (5%  8%)). Yield: 101 mg 
(79%). m.p. 219-220 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.19 (s, 1H), 7.82–7.74 (m, 2H), 
7.42–7.38 (m, 2H), 7.37 (s, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.71 (t, J = 7.0 Hz, 2H), 1.47 ppm (s br, 2H); 13C 
NMR (101 MHz, DMSO-d6) δ 156.3, 153.01, 149.1, 139.9, 139.6, 133.0, 129.6, 122.9, 119.2, 43.6, 39.3 ppm 
(merged with DMSO); HRMS-ESI: m/z calcd for C13H15N6+: 255.1353 [M+H+], found: 255.1355. 
 
N-(4-(6-Aminopurin-9-yl)phenethyl)formamide 
 
Following the general procedure using 4-bromophenethyl amine (151 mg, 0.75 mmol) and DMF/H2O (1 mL, 
4:1 v/v) as solvent provided N-(4-(6-amino-9H-purin-9-yl)phenethyl)formamide as a pale yellow solid after 
semi-automated flash chromatography (Biotage SNAP 10g, MeOH in CH2Cl2 (5%  9%)). Yield: 112 mg 
(79%). m.p. 169-170 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.21 (s, 1H), 8.11 (s, 1H), 8.02 (d, J 
= 1.6 Hz, 1H), 7.81 (d, J = 8.5 Hz, 2H), 7.46–7.40 (m, 2H), 7.37 (s, 2H), 3.42–3.38 (m, 2H), 2.82 ppm (t, J = 
7.1 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 161.1, 156.3, 153.1, 149.1, 139.6, 138.7, 133.3, 129.7, 
122.9, 119.3, 38.6, 34.5 ppm. HRMS-ESI: m/z calcd for C14H15N6O+: 283.1302 [M+H+], found: 283.1295. 
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Synthetic	procedure	for	N‐arylation	of	various	purines	(Table	3)	
Preparation of 8-methyltheophylline (4d) 
 
A sealed vial containing 5,6-diamino-1,3-dimethyluracil hydrate (565 mg, 3.0 mmol), acetic anhydride (0.31 
mL, 3.3 mmol) and pyridine (6 mL) was heated in a microwave reactor (Emrys Creator) at 110 °C for 20 min 
to give a red mixture with a precipitate. The solvent was evaporated under vacuum to dryness. The resulting 
amide was converted to benzimidazole by treatment with t-BuOK (1.01 g, 9.0 mmol) in isopropyl alcohol 
(14 mL) at 60 °C. After 16 hours, the reaction mixture was cooled to RT, silica (5 g) was added and the 
mixture was concentrated to dryness on a rotary evaporator. The dry residue was purified by semi-automated 
flash column chromatography (Biotage SNAP 25 g, MeOH in CH2Cl2 (3%  4.5%)), to provide 382 mg 
(66%) of 8-methyltheophylline (4d). m.p. 322-324 °C (lit. 325 °C7); 1H NMR (400 MHz, DMSO) δ 3.39 (s, 
3H), 3.21 (s, 3H), 2.36 ppm (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 153.9, 151.2, 150.4, 148.1, 106.1, 
29.7, 27.6, 14.3 ppm. HRMS-ESI: m/z calcd for C14H15N6O+: 283.1302 [M+H+], found: 283.1295. 
 
General procedure A - purine, 2,6-diaminopurine, theophylline and 8-methyltheophylline (4a-d): A 
reaction tube equipped with a magnetic stirring bar was charged with CuBr (3.6 mg, 0.025 mmol), ligand 
(L3, 14.9 mg, 0.05 mmol), sodium ascorbate (10 mg, 0.05 mmol), the purine substrate (4a, 4b, 4c or 4d, 0.50 
mmol) and KOH (56.1 mg, 1.0 mmol). The tube was sealed with a rubber septum, evacuated and back-filled 
with nitrogen three times. Then DMF/H2O (4:1 v/v, 1 mL) and aryl halide (0.75 mmol) was added by 
syringe. The rubber septum was exchanged with a cap designed to withstand moderate pressure under a 
stream of nitrogen and the reaction tube was placed in a preheated oil bath at 120 °C. After 21 hours or 48 
hours, the reaction mixture was cooled to RT, silica (1.5 g) was added and the mixture was concentrated to 
dryness on a rotary evaporator. The dry residue was purified by semi-automated flash column 
chromatography.  
 
General procedure B - guanine and hypoxanthine (4e and 4f): A reaction tube equipped with a magnetic 
stirring bar was charged with CuBr (3.6 mg, 0.025 mmol), ligand (L3, 14.9 mg, 0.05 mmol), the purine 
substrate (4e or 4f, 0.50 mmol) and KOH (56.1 mg, 1.0 mmol). The tube was sealed with a rubber septum, 
evacuated and back-filled with nitrogen three times. Then DMSO/H2O (4:1 v/v, 1 mL) and aryl halide (0.75 
mmol) was added by syringe. The rubber septum was exchanged with a cap designed to withstand moderate 
pressure under a stream of nitrogen and the reaction tube was placed in a preheated oil bath at 120 °C. After 
6-48 hours, the reaction mixture was cooled to RT, silica (1.5 g) was added and the mixture concentrated to 
dryness on a rotary evaporator at 60 °C. The dry residue was purified by semi-automated flash column 
chromatography. 
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9-Phenylpurine (5a) and 7-phenylpurine(6a) 
    
Using iodobenzene: Synthesised by general procedure A using iodobenzene (153 mg, 0.75 mmol) and 
heating for 21 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (2%  3%)) gave 61 mg (62%) of 9-phenylpurine (5a) and 7 mg (7%) of 7-phenylpurine (6a), both 
products as pale brown solids. 
Using bromobenzene: Synthesised by general procedure A using bromobenzene (118 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (2%  3%)) gave 63 mg (64%) of 9-phenylpurine (5a) and 3 mg (3%) of 7-phenylpurine (6a), both 
products as pale brown solids. 
9-phenylpurine (5a): 1H NMR (400 MHz, CDCl3) δ 9.24 (s, 1H), 9.05 (s, 1H), 8.38 (s, 1H), 7.78–7.67 (m, 
2H), 7.66–7.55 (m, 2H), 7.53–7.44 ppm (m, 1H). 13C NMR (101 MHz, CDCl3) δ 153.5, 151.2, 149.4, 144.3, 
134.7, 134.3, 130.2, 128.7, 123.6 ppm; HRMS-ESI: m/z calcd for C11H9N4+: 197.0822 [M+H+], found: 
197.0823.8† 
7-phenylpurine (6a): 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 9.06 (s, 1H), 8.47 (s, 1H), 7.68–7.62 (m, 
2H), 7.59–7.51 ppm (m, 3H). 13C NMR (101 MHz, CDCl3) δ 161.3, 154.0, 146.9, 140.8, 135.0, 130.8, 129.4, 
125.3, 123.7 ppm; HRMS-ESI: m/z calcd for C11H9N4+: 197.0822 [M+H+], found: 197.0826.9‡ 
 
9-Phenylpurine-2,6-diamine (5b) 
  
Using iodobenzene: Synthesised by general procedure A using iodobenzene (153 mg, 0.75 mmol) and 
heating for 21 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (4%  5%)) gave 106 mg (94%) of the title compound as a white solid.1 
Using bromobenzene: Synthesised by general procedure A using bromobenzene (118 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (4%  5%)) gave 68 mg (60%) of the title compound as a white solid.  
 
  
                                                     
† In accordance with the 1H-NMR reported by Hayashi et al. No 13C-NMR has been reported previously. 
‡ 1H-NMR reported by Laufer et al. used DMSO-d6 as solvent. No 13C-NMR has been reported previously. 
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7-Phenyltheophylline (6c) 
  
Using iodobenzene: Synthesised by general procedure A using iodobenzene (153 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, EtOAc in 
PE (50%  100%)) gave 101 mg (79%) of the title compound as a white solid.10  
Using bromobenzene: Synthesised by general procedure A using bromobenzene (118 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, EtOAc in 
PE (50%  100%)) gave 100 mg (78%) of the title compound as a white solid.  
 
8-methyl-7-phenyltheophylline (6d) 
  
Using iodobenzene: Synthesised by general procedure A using iodobenzene (153 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, EtOAc in 
PE (60%  100%)) gave 16 mg (12%) of the title compound as a white solid.  
Using bromobenzene: Synthesised by general procedure A using bromobenzene (118 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, EtOAc in 
PE (60%  100%)) gave 13 mg (10%) of the title compound as a white solid. 
m.p. 230-231 °C (lit. 235 °C11); 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.49 (m, 3H), 7.38 – 7.28 (m, 2H), 
3.63 (s, 3H), 3.34 (s, 3H), 2.36 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 154.3, 151.8, 151.2, 148.6, 
135.0, 129.6, 129.5, 127.1, 108.3, 29.9, 28.1, 13.9 ppm; HRMS-ESI: m/z calcd for C14H15N4O2+: 271.1190 
[M+H+], found: 271.1184. 
 
9-Phenylguanine (5e) and 7-phenylguanine (6e) 
 
Using iodobenzene: Synthesised by general procedure B using iodobenzene (153 mg, 0.75 mmol) and 
heating for 21 hours. Purification by semi-automated flash chromatography (Biotage SNAP 25 g, MeOH in 
CH2Cl2 (4%  8%)) gave a mixture of two isomers: 9-phenylguanine (5e) and 7-phenylguanine (6e) that 
were separated on HPLC (5-22% MeCN in H2O (0-5 min), Rt(6e) = 3.9 min, Rt(5e) = 4.7 min) to give 68 mg 
(60%) of 5e as a white solid and 24 mg (21%) of 6e as a pale yellow solid.3,12  
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Using bromobenzene: Synthesised by general procedure B using bromobenzene (118 mg, 0.75 mmol) and 
heating for 48 hours. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (5%  10%)) gave a mixture of two isomers: 9-phenylguanine (5e) and 7-phenylguanine (6e) that 
were separated on HPLC (5-22% MeCN in H2O (0-5 min), Rt(6e) = 3.9 min, Rt(5e) = 4.7 min) to give 67 mg 
(59%) of 5e as a white solid and 15 mg (13%) of 6e as a pale yellow solid.  
 
9-Phenylhypoxanthine (5f) and 7-phenylhypoxanthine (6f) 
 
Using iodobenzene: Synthesised by general procedure B using iodobenzene (153 mg, 0.75 mmol) and 
heating for 3 hours, after which the starting material was almost consumed, and diarylated products had 
started to form. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  5%)) gave a mixture of two isomers: 9-phenylhypoxanthine (5f) and 7-phenylhypoxanthine 
(6f) that were separated on HPLC (10-21% MeCN in H2O (0-6 min), Rt(6f) = 4.4 min, Rt(5f) = 5.3 min) to 
give 46 mg (43%) of 5f and 15 mg (14%) of 6f, both as white solids.  
Using bromobenzene: Synthesised by general procedure B using bromobenzene (118 mg, 0.75 mmol) and 
heating for 32 hours, after which the starting material was almost consumed, and diarylated products had 
started to form. Purification by semi-automated flash chromatography (Biotage SNAP 10 g, MeOH in 
CH2Cl2 (3%  5%)) gave a mixture of two isomers: 9-phenylhypoxanthine (5f) and 7-phenylhypoxanthine 
(6f) that were separated on HPLC (10-21% MeCN in H2O (0-6 min), Rt(6f) = 4.4 min, Rt(5f) = 5.3 min) to 
give 51 mg (48%) of 5f and 12 mg (11%) of 6f, both as white solids.  
9-phenylhypoxanthine (5f): m.p. 317-318 °C (lit. 316-318 °C13); 1H NMR (400 MHz, DMSO-d6) δ 12.47 (s, 
1H), 8.47 (s, 1H), 8.09 (s, 1H), 7.83–7.69 (m, 2H), 7.67–7.55 (m, 2H), 7.55–7.44 ppm (m, 1H). 13C NMR 
(101 MHz, DMSO-d6) δ 156.7, 147.9, 146.1, 139.4, 134.5, 129.5, 128.1, 124.8, 123.8 ppm; HRMS-ESI: m/z 
calcd for C11H9N4O+: 213.0771 [M+H+], found: 213.0761.13 
7-phenylhypoxanthine (6f): m.p. 295-296 °C (lit. 295-297 °C14); 1H NMR (400 MHz, DMSO-d6) δ 12.43 
(s, 1H), 8.51 (s, 1H), 8.06 (s, 1H), 7.68–7.59 (m, 2H), 7.57–7.51 (m, 2H), 7.51–7.44 ppm (m, 1H). 13C NMR 
(101 MHz, DMSO-d6) δ 158.2, 153.6, 145.2, 144.0, 135.4, 128.9, 128.2, 125.2, 114.6 ppm; HRMS-ESI: m/z 
calcd for C11H9N4+: 213.0771 [M+H+], found: 213.0761.14 
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NMR‐spectra	
N4,N7-dimethyl-1,10-phenanthroline-4,7-diamine (Ligand L2) 
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N4,N7-Bis(2-hydroxyethyl)-1,10-phenanthroline-4,7-diamine (Ligand L3). 
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9-phenyladenine (2) 
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3-(6-Aminopurin-9-yl)phenol (3a) 
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9-(4-Aminophenyl)purin-6-amine (3b) 
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3-(6-Aminopurin-9-yl)benzoic acid (3c) 
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3-(6-Aminopurin-9-yl)benzonitrile (3d) 
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9-(3-(Trifluoromethyl)phenyl)purin-6-amine (3e) 
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9-(3-Nitrophenyl)purin-6-amine (3f) 
 
  
S24 
 
9-(2-Chlorophenyl)purin-6-amine (3g) 
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9-(o-Tolyl)purin-6-amine (3h) 
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9-(Pyridin-2-yl)purin-6-amine (3i) 
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9-(6-Methylpyridin-3-yl)purin-6-amine (3j) 
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9-(Thiophen-3-yl)purin-6-amine (3k) 
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4-(6-Aminopurin-9-yl)phenol (3l) 
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1-(4-(6-Aminopurin-9-yl)phenyl)ethan-1-one (3m) 
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9-(4-Fluorophenyl)purin-6-amine (3n) 
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2-(4-(6-Aminopurin-9-yl)phenyl)ethan-1-ol (3o) 
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9-(4-(2-Aminoethyl)phenyl)purin-6-amine (3p) 
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HSQC of 3p:  
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N-(4-(6-Aminopurin-9-yl)phenethyl)formamide 
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8-Methyltheophylline (4d) 
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9-Phenylpurine (5a) 
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NOESY of 5a 
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9-Phenylpurine-2,6-diamine (5b) 
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9-Phenylguanine (5e) 
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9-Phenylhypoxanthine (5f) 
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HMBC of 5f 
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7-Phenylpurine (6a) 
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NOESY of 6a 
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7-Phenyltheophylline (6c) 
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8-methyl-7-phenyltheophylline (6d) 
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7-phenylguanine (6e) 
S48 
 
7-Phenylhypoxanthine (6f) 
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HMBC of 6f 
 
 
